Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)‘s stock had its “buy” rating reaffirmed by equities research analysts at B. Riley in a research note issued to investors on Monday. They currently have a $50.00 price objective on the specialty pharmaceutical company’s stock. B. Riley’s target price would suggest a potential upside of 29.20% from the company’s previous close.

SUPN has been the topic of a number of other reports. Piper Jaffray Companies reaffirmed a “hold” rating and set a $41.00 target price on shares of Supernus Pharmaceuticals in a research report on Tuesday, September 26th. Cantor Fitzgerald reissued a “buy” rating and issued a $49.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, September 27th. BidaskClub raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 17th. FBR & Co started coverage on Supernus Pharmaceuticals in a research report on Thursday, October 19th. They issued a “buy” rating and a $53.00 price target for the company. Finally, SunTrust Banks, Inc. reissued a “buy” rating and issued a $61.00 price target on shares of Supernus Pharmaceuticals in a research report on Friday, November 3rd. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $49.60.

Supernus Pharmaceuticals (NASDAQ SUPN) opened at $38.70 on Monday. Supernus Pharmaceuticals has a 12-month low of $20.55 and a 12-month high of $50.04. The firm has a market capitalization of $1,980.00, a P/E ratio of 35.85, a PEG ratio of 1.61 and a beta of 1.30.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.02. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The company had revenue of $80.40 million for the quarter, compared to analyst estimates of $78.74 million. The firm’s revenue was up 41.5% compared to the same quarter last year. equities research analysts predict that Supernus Pharmaceuticals will post 1.07 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://theolympiareport.com/2017/11/22/b-riley-reiterates-buy-rating-for-supernus-pharmaceuticals-inc-supn.html.

In other Supernus Pharmaceuticals news, CFO Gregory S. Patrick sold 50,000 shares of the company’s stock in a transaction on Friday, September 8th. The stock was sold at an average price of $47.60, for a total value of $2,380,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Padmanabh P. Bhatt sold 5,000 shares of the company’s stock in a transaction on Friday, September 8th. The shares were sold at an average price of $49.86, for a total value of $249,300.00. Following the completion of the transaction, the senior vice president now owns 12,500 shares of the company’s stock, valued at approximately $623,250. The disclosure for this sale can be found here. Insiders sold a total of 150,000 shares of company stock valued at $7,055,350 in the last 90 days. Corporate insiders own 6.70% of the company’s stock.

A number of large investors have recently made changes to their positions in SUPN. Meeder Asset Management Inc. grew its stake in Supernus Pharmaceuticals by 3,455.2% in the 2nd quarter. Meeder Asset Management Inc. now owns 2,382 shares of the specialty pharmaceutical company’s stock valued at $103,000 after purchasing an additional 2,315 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Supernus Pharmaceuticals by 278.2% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock worth $130,000 after acquiring an additional 2,220 shares during the period. Riverhead Capital Management LLC grew its stake in shares of Supernus Pharmaceuticals by 91.4% during the 2nd quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock worth $132,000 after acquiring an additional 1,462 shares during the period. Advisor Group Inc. grew its stake in shares of Supernus Pharmaceuticals by 13.7% during the 2nd quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock worth $145,000 after acquiring an additional 410 shares during the period. Finally, Victory Capital Management Inc. grew its stake in shares of Supernus Pharmaceuticals by 17.7% during the 2nd quarter. Victory Capital Management Inc. now owns 3,441 shares of the specialty pharmaceutical company’s stock worth $148,000 after acquiring an additional 517 shares during the period. Hedge funds and other institutional investors own 94.70% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.